实用癌症杂志
實用癌癥雜誌
실용암증잡지
THE PRACTICAL JOURNAL OF CANCER
2014年
7期
886-888
,共3页
李涛%郭洪敏%田宝方%刘俊宾
李濤%郭洪敏%田寶方%劉俊賓
리도%곽홍민%전보방%류준빈
骨肉瘤%大剂量甲氨蝶呤%顺铂%免疫功能
骨肉瘤%大劑量甲氨蝶呤%順鉑%免疫功能
골육류%대제량갑안접령%순박%면역공능
Osteosarcoma%HD-MTX%PPD%Immune function
目的:探讨大剂量甲氨蝶呤联合顺铂治疗骨肉瘤患者的临床疗效。方法选择60例骨肉瘤患者作为研究对象。按照患者住院时间先后顺序分组为对照组和观察组。对照组:采用顺铂治疗,80 mg/m2,静脉滴入,1次/天;观察组:采用大剂量甲氨蝶呤联合顺铂治疗,其中采用顺铂80 mg/m2,静脉滴入,1次/天;甲氨蝶呤,6.0~8.0 g/m2,静脉滴注6 h,之后第4 h采用甲酰四氢叶酸钙解救,15 mg静脉注射,q3 h ×9次,肌肉注射15 mg,q6h ×(6~8)次。观察2组患者的近、远期疗效和不良反应及对细胞因子的影响。结果治疗后,观察组1、2、3年生存率分别为76.67%(23/30)、53.33%(16/30)、36.67%(11/30),对照组分别为73.33%(22/30)、36.67%(11/30)、20.00%(6/30),2组1年生存率比较,P>0.05;而2组2、3年生存率比较,P<0.05。此外,2组患者近期临床疗效和不良反应比较,P<0.05。2组患者治疗后血清IL-2和TNF-α及IFN-γ水平与治疗前比较,均出现明显上升,但观察组升高较为显著(P<0.05)。结论相比顺铂来说,大剂量甲氨蝶呤联合顺铂治疗骨肉瘤患者,能提高近远期疗效,且不良反应少,同时还能有效改善患者免疫功能,提高患者抵抗力。
目的:探討大劑量甲氨蝶呤聯閤順鉑治療骨肉瘤患者的臨床療效。方法選擇60例骨肉瘤患者作為研究對象。按照患者住院時間先後順序分組為對照組和觀察組。對照組:採用順鉑治療,80 mg/m2,靜脈滴入,1次/天;觀察組:採用大劑量甲氨蝶呤聯閤順鉑治療,其中採用順鉑80 mg/m2,靜脈滴入,1次/天;甲氨蝶呤,6.0~8.0 g/m2,靜脈滴註6 h,之後第4 h採用甲酰四氫葉痠鈣解救,15 mg靜脈註射,q3 h ×9次,肌肉註射15 mg,q6h ×(6~8)次。觀察2組患者的近、遠期療效和不良反應及對細胞因子的影響。結果治療後,觀察組1、2、3年生存率分彆為76.67%(23/30)、53.33%(16/30)、36.67%(11/30),對照組分彆為73.33%(22/30)、36.67%(11/30)、20.00%(6/30),2組1年生存率比較,P>0.05;而2組2、3年生存率比較,P<0.05。此外,2組患者近期臨床療效和不良反應比較,P<0.05。2組患者治療後血清IL-2和TNF-α及IFN-γ水平與治療前比較,均齣現明顯上升,但觀察組升高較為顯著(P<0.05)。結論相比順鉑來說,大劑量甲氨蝶呤聯閤順鉑治療骨肉瘤患者,能提高近遠期療效,且不良反應少,同時還能有效改善患者免疫功能,提高患者牴抗力。
목적:탐토대제량갑안접령연합순박치료골육류환자적림상료효。방법선택60례골육류환자작위연구대상。안조환자주원시간선후순서분조위대조조화관찰조。대조조:채용순박치료,80 mg/m2,정맥적입,1차/천;관찰조:채용대제량갑안접령연합순박치료,기중채용순박80 mg/m2,정맥적입,1차/천;갑안접령,6.0~8.0 g/m2,정맥적주6 h,지후제4 h채용갑선사경협산개해구,15 mg정맥주사,q3 h ×9차,기육주사15 mg,q6h ×(6~8)차。관찰2조환자적근、원기료효화불량반응급대세포인자적영향。결과치료후,관찰조1、2、3년생존솔분별위76.67%(23/30)、53.33%(16/30)、36.67%(11/30),대조조분별위73.33%(22/30)、36.67%(11/30)、20.00%(6/30),2조1년생존솔비교,P>0.05;이2조2、3년생존솔비교,P<0.05。차외,2조환자근기림상료효화불량반응비교,P<0.05。2조환자치료후혈청IL-2화TNF-α급IFN-γ수평여치료전비교,균출현명현상승,단관찰조승고교위현저(P<0.05)。결론상비순박래설,대제량갑안접령연합순박치료골육류환자,능제고근원기료효,차불량반응소,동시환능유효개선환자면역공능,제고환자저항력。
Objective To investigate the clinical effects of high dose Methotrexate ( HD-MTX) combined with Cisplatin ( PPD) in the treatment of osteosarcoma .Methods 60 patients with osteosarcoma were chosen as the research objects .According to hospitalization time sequence ,they were divided into the control group and the observation group .All patients were treated with PPD 80 mg/m2 ,1/d.The observation group was added with HD-MTX,6.0~8.0 g/m2 ,intravenous drip 6 hours,4 hours later with leucovorin calcium to free ,15 mg intravenous injection ,q3h ×9times;intramuscular 15 mg,q6h ×6~8times.The recent effi-cacy,long-term efficacy,adverse reactions and the influence to cytokines of the 2 groups were observed .Results After treatment, 1-,2-,3-year survival rates of the observation group and the control group were 76.67%(23/30),53.33%(16/30),36.67%(11/30),and 73.33%(22/30),36.67%(11/30),20.00%(6/30).There was no significant difference between the 2 groups in 1-year survival rate (P<0.05),but 2-and 3-year survival rates was significantly different (P<0.05).In addition,the difference of the recent clinical curative effects and adverse reactions in both groups were also statistically significant (P<0.05).After treat-ment ,serum IL-2 and TNF alpha and IFN-gamma levels of all patients increased significantly ,but the observation group was high-er(P<0.05).Conclusion HD-MTX combined with PPD therapy can improve the patients ’recent and long -term efficacy,re-duce adverse reactions ,and improve immune function .